Frontera's APEX Technology & Manufacturing Platform is an innovative adeno-associated virus (AAV) gene expression system. It includes novel and clinically validated AAV vectors, efficient and fully-integrated CMC processes, and access to early clinical data, making it possible to develop novel gene therapy products with quicker speed-to-market and lower cost.
- World-class execution – leveraging fully integrated teams – across disease biology, gene therapy vector design, translational sciences, process and analytical development, in-house GMP manufacturing and clinical research.
- State-of-the-art GMP facilities.
- World-class and proven team in gene therapy R&D, having been in leading roles or as founders for some of the most successful and innovative gene therapy and gene editing products and companies.
- Early access to clinical data made possible by Frontera’s unique scientific model.
Product development in gene therapy has historically focused on a limited number of rare monogenic disorders. The possibilities for gene therapy, however, are vastly greater. Frontera is realizing this potential with a pipeline that spans across not only orphan diseases, but also in larger patient markets – including Ophthalmology, Hematology, Cardiovascular and Metabolic Diseases.
Board of Directors
Wei Li, Ph.D.
Chairman, Founding Partner of Creacion Ventures
Carl Gordon, Ph.D.
Managing Partner, OrbiMed Advisors
David Wang, M.D., Ph.D.
Partner, OrbiMed Advisors
Ching Zhu, Ph.D.
Founding Partner of Creacion Ventures
Xinyan Li, Ph.D.
Co-Founder & CEO
Partner, Boyu Capital
Managing Director, Sequoia Capital China
Frontera Therapeutics Completes $160 Million Series B Financing to Fund Clinical Development and Manufacturing Capabilities
FDA clears Investigational New Drug (IND) application for lead gene therapy product candidate, FT-001, for the treatment of a rare inherited eye disease leading to severe visual impairment that may result in blindness. Investors in the $160 million Series B round include Boyu Capital, Sequoia China, and existing investors OrbiMed and Creacion Ventures, who were […]Read More